Agilent Technologies (A) investor relations material

Financial performance and growth drivers

• Achieved 6.3% revenue growth and 130 basis points margin expansion, driven by Ignite transformation and strong performance across diagnostics, forensics, semiconductors, and pharma.

• EPS grew 14%, exceeding guidance, with broad-based growth in C&AM, diagnostics, and semiconductors.

• Book-to-bill ratio remained above one for the ninth consecutive quarter, indicating sustained demand.

• Digital orders grew 9% overall and 20% ex-China, reflecting strong digital adoption.

• Margin expansion is expected to continue, supported by innovation, operational efficiency, and AI initiatives.

Innovation, product launches, and technology refresh

• Major product launches at ASMS, including the 9500 ICP-MS and new GC platforms, are driving tech refresh cycles, especially in semiconductors.

• Infinity III and Pro iQ platforms are fueling replacement cycles and market share gains.

• Altura columns family, including new GLP-1 and PFAS columns, is gaining traction in top biopharma companies.

• AI partnerships with OpenAI and BCG aim to accelerate software innovation and customer connectivity.

• AI Center of Excellence established, led by a Chief AI Officer, to drive enterprise-wide deployment.

Market and segment performance

• Semiconductors and batteries represent $400 million and $250 million opportunities, respectively, and are expected to be outsized growth drivers.

• C&AM delivered high single-digit growth, with advanced materials and battery segments performing strongly.

• Biopharma saw its fifth straight quarter of mid-single digit growth, with biotech up low double digits and small molecule up low single digits.

• Diagnostics business grew 11% in Q2, supported by demographic trends and recent M&A, including Biocare.

• China was soft, down 9%, but biopharma in China grew high teens; improvement expected by 2027.